Depression Clinical Trials in Ohio

39 recruiting studies across 2 cities

Browse by City

All Trials in Ohio

Phase

Trial	Phase	Sponsor	Dist.
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A	LivaNova	<1 mi
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)	N/A	Abbott Medical Devices	<1 mi
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms	Phase 3	Janssen Research & Development, LLC	<1 mi
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder	Phase 3	Intra-Cellular Therapies, Inc.	<1 mi
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder	Phase 2	AbbVie	<1 mi
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)	Phase 2	atai Therapeutics, Inc.	<1 mi
E-Mindfulness Approaches for Living After Breast Cancer	Phase 3	NRG Oncology	<1 mi
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer	Phase 2	Alan Davis	<1 mi
Mechanisms of Rumination Change in Adolescent Depression	N/A	Ohio State University	<1 mi
The Mom and Infant Outcomes (MOMI) Study	N/A	Ohio State University	<1 mi
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder	Phase 2	AbbVie	<1 mi
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression	Phase 2	Draig Therapeutics Ltd	<1 mi
A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A	Matthew Southward, PhD	<1 mi
Mindfulness-based Psilocybin Therapy for PTSD	Phase 2	Anthony P King	<1 mi
Teenthrive 2: Treatments for Improving Mood in Teens	N/A	Butler Hospital	<1 mi
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety	Phase 2	Ohio State University	<1 mi
Virtual Poetry Workshops to Enhance Patient Well Being and Reduce Anxiety	N/A	Ohio State University	<1 mi
Positive Processes and Transition to Health (PATH)	N/A	Case Western Reserve University	<1 mi
Positive Processes and Transition to Health - Single-Session (PATH-SS)	N/A	Case Western Reserve University	<1 mi
Developing Resilience and Anxiety Management Through the Arts	N/A	Case Western Reserve University	<1 mi
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.	Phase 3	AbbVie	<1 mi
Virtual Patient Groups for Sarcoidosis Associated Fatigue	N/A	The Cleveland Clinic	<1 mi
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)	Phase 3	Definium Therapeutics US, Inc.	<1 mi
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients	Phase 3	Intra-Cellular Therapies, Inc.	7 mi
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women	N/A	BTL Industries Ltd.	7 mi
ALTO-207 in Adults With Treatment-resistant Depression (TRD)	Phase 2	Alto Neuroscience	7 mi
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)	Phase 2	Seaport Therapeutics	10 mi
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder	Phase 2	Syndeio Biosciences, Inc	10 mi
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)	Phase 3	Xenon Pharmaceuticals Inc.	10 mi
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder	Phase 2	Syndeio Biosciences, Inc	10 mi
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor	Phase 4	Neurocrine Biosciences	10 mi
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)	Phase 2	Autobahn Therapeutics, Inc.	10 mi
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	12 mi
ALTO-100 in Bipolar Disorder With Depression (BD-D)	Phase 2	Alto Neuroscience	12 mi
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	17 mi
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response	Phase 2	ACADIA Pharmaceuticals Inc.	46 mi
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"	Phase 3	Cybin IRL Limited	46 mi
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder	Phase 3	Xenon Pharmaceuticals Inc.	46 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.